Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Two CYP2C9 variants--*2 (Arg144Cys) and *3 (Ile359Leu)--are associated with reduced enzyme activity and impaired substrate metabolism. We identified 1,073 incident users of sulfonylureas in Tayside, Scotland, and assess...

Full description

Bibliographic Details
Main Authors: Zhou, K, Donnelly, L, Burch, L, Tavendale, R, Doney, A, Leese, G, Hattersley, A, McCarthy, M, Morris, A, Lang, C, Palmer, C, Pearson, E
Format: Journal article
Language:English
Published: 2010